NOVEL COMPOUNDS avB6 INTEGRIN ANTAGONISTS.

Abstract

A compound of formula (I): being 4-(3-Fluoro-3-(2-(5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-2-yl) ethyl) pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy) phenyl) butanoic acid, or a salt thereof.

1 . A method of treating a cancer in a human in need thereof comprising administering to the human a therapeutically effective amount of (S)-4-((S)-3-fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl)butanoic acid 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         2 . A method of treating a cancer in a human in need thereof comprising administering to the human a therapeutically effective amount of (S)-4-((S)-3-fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl)butanoic acid citrate salt. 
     
     
         3 . The method according to  claim 1 , where the cancer is selected from endometrial cancer, basal cell cancer, liver cancer, colon cancer, cervical cancer, oral cancer, pancreatic cancer, breast cancer, ovarian cancer, Kaposi's sarcoma, giant cell tumours, cancer associated with stroma, and solid tumours. 
     
     
         4 . The method according to  claim 2 , where the cancer is selected from endometrial cancer, basal cell cancer, liver cancer, colon cancer, cervical cancer, oral cancer, pancreatic cancer, breast cancer, ovarian cancer, Kaposi's sarcoma, giant cell tumours, cancer associated with stroma, and solid tumours. 
     
     
         5 . A method of treating a cancer in a human in need thereof comprising administering a therapeutically effective amount to the human of a combination comprising (S)-4-((S)-3-fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl)butanoic acid 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and a cancer therapy agent. 
     
     
         6 . A method of treating a cancer in a human in need thereof comprising administering a therapeutically effective amount to the human of a combination comprising (S)-4-((S)-3-fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl)butanoic acid citrate salt and a cancer therapy agent. 
     
     
         7 . The method according to  claim 5 , wherein the cancer is selected from endometrial cancer, basal cell cancer, liver cancer, colon cancer, cervical cancer, oral cancer, pancreatic cancer, breast cancer, ovarian cancer, Kaposi's sarcoma, giant cell tumours, cancer associated with stroma, and solid tumours. 
     
     
         8 . The method according to  claim 6 , wherein the cancer is selected from endometrial cancer, basal cell cancer, liver cancer, colon cancer, cervical cancer, oral cancer, pancreatic cancer, breast cancer, ovarian cancer, Kaposi's sarcoma, giant cell tumours, cancer associated with stroma, and solid tumours. 
     
     
         9 . The method of  claim 5 , wherein the cancer therapy agent is selected from chemotherapy, radiotherapy, targeted agents, immunotherapy, and cell or gene therapy. 
     
     
         10 . The method of  claim 6 , wherein the cancer therapy agent is selected from chemotherapy, radiotherapy, targeted agents, immunotherapy, and cell or gene therapy. 
     
     
         11 . A combination comprising of (S)-4-((S)-3-fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl)butanoic acid 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and a cancer therapy agent. 
     
     
         12 . A combination comprising of (S)-4-((S)-3-fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl)butanoic acid citrate salt and a cancer therapy agent. 
     
     
         13 . A combination according to  claim 11 , wherein the cancer therapy agent is selected from chemotherapy, radiotherapy, targeted agents, immunotherapy, and cell or gene therapy. 
     
     
         14 . A combination according to  claim 12 , wherein the cancer therapy agent is selected from chemotherapy, radiotherapy, targeted agents, immunotherapy, and cell or gene therapy. 
     
     
         15 . A compound of formula (I) which is (S)-4-((S)-3-fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl)butanoic acid citrate salt.